Affiliation:
1. Transplant Institute, Tampa General Hospital, Tampa, FL 33606, USA
Abstract
Improvements in downstaging therapies have expanded the indications for liver transplantation (LT) for hepatocellular carcinoma (HCC). Patients with more advanced disease are now considered candidates due to advancements in radiation therapy, combination therapies, and immunotherapy. Combination stereotactic body radiation therapy (SBRT) and trans-arterial chemoembolization (TACE) has been shown to be superior to the historic treatment, sorafenib, in patients with macrovascular invasion. These patients are now candidates for LT with stable disease after LRT. Patients with ruptured HCC and prolonged stability have also been shown to have acceptable outcomes. The role of neoadjuvant immunotherapy needs to be further defined and has the potential to further improve tumor control prior to transplant.
Reference58 articles.
1. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis;Mazzaferro;N. Engl. J. Med.,1996
2. Sorafenib in Advanced Hepatocellular Carcinoma;Llovet;N. Engl. J. Med.,2008
3. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival;Yao;Hepatology,2001
4. (2024, July 10). Committee Notes: Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exceptions for Hepatocellular Carcinoma 2023, Available online: https://optn.transplant.hrsa.gov/media/gqlnhrtn/20200804_nlrb_adult_hcc_guidance.pdf.
5. Podlasek, A., Abdulla, M., Broering, D., and Bzeizi, K. (2023). Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma. Cancers, 15.